Who owns SAB Biotherapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of SABS from SEC Form 13F filings across 87 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 87 institutions disclosed 68.4M shares of SAB Biotherapeutics, Inc. worth $266.8M — about 85.8% of shares outstanding; the largest disclosed holder is Caligan Partners LP. Source: SEC Form 13F filings, parsed by EvidInvest.
87
13F holders
$266.8M
value, 2026 filers
85.8%
of shares outstanding (68.4M sh)
32
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of SABS's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Caligan Partners LP | 8.0M | $31.1M | 1.5% | 10% | 0.0% |
| 2 | Vivo Capital, LLC | 7.3M | $28.5M | 2.6% | 9.2% | -36.1% |
| 3 | PERCEPTIVE ADVISORS LLC | 6.6M | $25.8M | 0.4% | 8.3% | +3.0% |
| 4 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.4M | $25.0M | 0.0% | 8% | +88.1% |
| 5 | RA CAPITAL MANAGEMENT, L.P. | 4.4M | $17.2M | 0.1% | 5.5% | 0.0% |
| 6 | Balyasny Asset Management L.P. | 3.8M | $14.7M | 0.0% | 4.7% | 0.0% |
| 7 | BlackRock, Inc. | 3.1M | $12.0M | 0.0% | 3.8% | +917.5% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 3.0M | $11.6M | 0.0% | 3.7% | +19.2% |
| 9 | Commodore Capital LP | 2.9M | $11.2M | 0.7% | 3.6% | -34.8% |
| 10 | MILLENNIUM MANAGEMENT LLC | 2.7M | $10.7M | 0.0% | 3.4% | -9.4% |
| 11 | Spruce Street Capital LP | 2.2M | $8.6M | 1.7% | 2.8% | 0.0% |
| 12 | Sessa Capital IM, L.P. | 2.2M | $8.6M | 0.1% | 2.8% | 0.0% |
| 13 | Affinity Asset Advisors, LLC | 1.5M | $5.9M | 0.3% | 1.9% | +165.2% |
| 14 | BOOTHBAY FUND MANAGEMENT, LLC | 1.5M | $5.8M | 0.1% | 1.9% | 0.0% |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 1.3M | $5.0M | 0.0% | 1.6% | +322.9% |
| 16 | Woodline Partners LP | 1.2M | $4.6M | 0.0% | 1.5% | -58.6% |
| 17 | Ensign Peak Advisors, Inc | 1.2M | $4.6M | 0.0% | 1.5% | -14.8% |
| 18 | Propel Bio Management, LLC | 1.1M | $4.2M | 2.2% | 1.3% | +6.3% |
| 19 | Soleus Capital Management, L.P. | 900,000 | $3.5M | 0.1% | 1.1% | -14.3% |
| 20 | Seven Fleet Capital Management LP | 736,077 | $2.9M | 0.5% | 0.9% | +636.1% |
| 21 | AMERIPRISE FINANCIAL INC | 611,019 | $2.4M | 0.0% | 0.8% | -58.6% |
| 22 | STATE STREET CORP | 530,831 | $2.1M | 0.0% | 0.7% | +615.1% |
| 23 | SUSQUEHANNA INTERNATIONAL GROUP, LLPNEW | 438,515 | $1.7M | 0.0% | 0.5% | new |
| 24 | DV EQUITIES, LLCNEW | 400,000 | $1.6M | 0.2% | 0.5% | new |
| 25 | AWM Investment Company, Inc. | 375,000 | $1.5M | 0.1% | 0.5% | -6.2% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.